Who
Herb Cross
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Jasper Therapeutics; Director, Apexigen; Chief Financial Officer, Atreca; Chief Financial Officer, ARMO BioSciences; Chief Financial Officer, Kalobios Pharmaceuticals; Chief Financial Officer, Affymax; VP of Finance, Facet Biotech; Corp Controller/Prin Acctg Off, Pdl Biopharma.
In numbers
- Trades disclosed
- 76
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $514K
- Companies
- 9
- Companies where not an officer
- 1
- First trade
- 29 Jul 2005
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 Feb 2024filed 20 Feb 2024 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 22 Sep 2023filed 26 Sep 2023 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —550,000 at $0.00 | filing |
| 23 Aug 2023filed 25 Aug 2023 | Apexigenoption or derivative | SEC FORM 4 Code D | —34,084 | filing |
| 23 Aug 2023filed 25 Aug 2023 | Apexigenoption or derivative | SEC FORM 4 Code D | —100,000 | filing |
| 2 Aug 2023filed 4 Aug 2023 | Atreca | SEC FORM 4 Sold | $5,2135,487 at $0.95 | filing |
| 9 Feb 2023filed 13 Feb 2023 | Atrecaoption or derivative | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 9 Feb 2023filed 13 Feb 2023 | Atreca | SEC FORM 4 Code A | —43,750 at $0.00 | filing |
| 29 Sep 2022filed 3 Oct 2022 | Apexigenoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Sep 2022filed 20 Sep 2022 | Atreca | SEC FORM 4 Sold | $14K7,646 at $1.78 | filing |
| 13 Jun 2022filed 15 Jun 2022 | Atrecaoption or derivative | SEC FORM 4 Code A | —95,000 | filing |
| 13 Jun 2022filed 15 Jun 2022 | Atrecaoption or derivative | SEC FORM 4 Code D | —95,000 at $0.00 | filing |
| 13 Jun 2022filed 15 Jun 2022 | Atrecaoption or derivative | SEC FORM 4 Code A | —224,999 | filing |
| 13 Jun 2022filed 15 Jun 2022 | Atrecaoption or derivative | SEC FORM 4 Code D | —224,999 at $0.00 | filing |
| 13 Jun 2022filed 15 Jun 2022 | Atrecaoption or derivative | SEC FORM 4 Code A | —97,000 | filing |
| 13 Jun 2022filed 15 Jun 2022 | Atrecaoption or derivative | SEC FORM 4 Code D | —97,000 at $0.00 | filing |
| 23 Dec 2021filed 28 Dec 2021 | Atrecaoption or derivative | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.